Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging.

Bose SK, Turkheimer FE, Howes OD, Mehta MA, Cunliffe R, Stokes PR, Grasby PM.

Schizophr Res. 2008 Dec;106(2-3):148-55. doi: 10.1016/j.schres.2008.09.011. Epub 2008 Oct 11.

PMID:
18849151
2.

Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study.

McGowan S, Lawrence AD, Sales T, Quested D, Grasby P.

Arch Gen Psychiatry. 2004 Feb;61(2):134-42.

PMID:
14757589
3.

Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.

Brück A, Aalto S, Nurmi E, Vahlberg T, Bergman J, Rinne JO.

Mov Disord. 2006 Jul;21(7):958-63.

PMID:
16550545
4.

Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.

Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD.

Am J Psychiatry. 2012 Nov;169(11):1203-10.

PMID:
23034655
5.

Elevated striatal dopamine function linked to prodromal signs of schizophrenia.

Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM.

Arch Gen Psychiatry. 2009 Jan;66(1):13-20. doi: 10.1001/archgenpsychiatry.2008.514.

PMID:
19124684
6.

Involvement of the basal ganglia in refractory epilepsy: an 18F-fluoro-L-DOPA PET study using 2 methods of analysis.

Bouilleret V, Semah F, Biraben A, Taussig D, Chassoux F, Syrota A, Ribeiro MJ.

J Nucl Med. 2005 Mar;46(3):540-7.

7.

Striatal 18F-dopa uptake: absence of an aging effect.

Eidelberg D, Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Margouleff D, Moeller JR, Patlak CS, Fahn S.

J Cereb Blood Flow Metab. 1993 Sep;13(5):881-8.

PMID:
8360294
8.

The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.

Sawle GV, Burn DJ, Morrish PK, Lammertsma AA, Snow BJ, Luthra S, Osman S, Brooks DJ.

Neurology. 1994 Jul;44(7):1292-7.

PMID:
8035933
9.

Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study.

Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Gründer G.

J Neurosci. 2007 Jul 25;27(30):8080-7.

10.

Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.

Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL.

Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):454-62. doi: 10.1007/s00259-008-0989-5. Epub 2008 Nov 27.

PMID:
19037637
11.

Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge.

Vernaleken I, Kumakura Y, Cumming P, Buchholz HG, Siessmeier T, Stoeter P, Müller MJ, Bartenstein P, Gründer G.

Neuroimage. 2006 May 1;30(4):1332-9. Epub 2006 Jan 24.

PMID:
16439159
12.

Modeling of fluorine-18-6-fluoro-L-Dopa in humans.

Wahl L, Nahmias C.

J Nucl Med. 1996 Mar;37(3):432-7.

14.

The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function.

Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD.

Neuroimage. 2010 Apr 1;50(2):524-531. doi: 10.1016/j.neuroimage.2009.12.058. Epub 2009 Dec 23.

15.

Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients.

Heinz A, Siessmeier T, Wrase J, Buchholz HG, Gründer G, Kumakura Y, Cumming P, Schreckenberger M, Smolka MN, Rösch F, Mann K, Bartenstein P.

Am J Psychiatry. 2005 Aug;162(8):1515-20.

PMID:
16055774
16.

Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia.

Huttunen J, Heinimaa M, Svirskis T, Nyman M, Kajander J, Forsback S, Solin O, Ilonen T, Korkeila J, Ristkari T, McGlashan T, Salokangas RK, Hietala J.

Biol Psychiatry. 2008 Jan 1;63(1):114-7. Epub 2007 Jul 26.

PMID:
17655830
17.

Net influx of plasma 6-[18F]fluoro-L-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli.

Siessmeier T, Kienast T, Wrase J, Larsen JL, Braus DF, Smolka MN, Buchholz HG, Schreckenberger M, Rösch F, Cumming P, Mann K, Bartenstein P, Heinz A.

Eur J Neurosci. 2006 Jul;24(1):305-13.

PMID:
16882026
18.

Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.

Kuwabara H, Cumming P, Reith J, Léger G, Diksic M, Evans AC, Gjedde A.

J Cereb Blood Flow Metab. 1993 Jan;13(1):43-56.

PMID:
8417009
19.

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS.

Ann Neurol. 1990 Oct;28(4):547-55.

PMID:
2132742
20.

A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system.

Torstenson R, Tedroff J, Hartvig P, Fasth KJ, Långström B.

J Cereb Blood Flow Metab. 1999 Oct;19(10):1142-9.

PMID:
10532639

Supplemental Content

Support Center